Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 59-70

  Flack, John M ^a   Graff, Alan ^b   Li, Wei ^c   Chavanu, Kathleen J ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Daiichi Sankyo Inc ^*

^c DAIICHI SANKYO INC   (United States)

Author keywords

Ambulatory BP; Angiotensin II receptor blocker; Antihypertensive; Hypertension; Losartan; Olmesartan

Indexed keywords

LOSARTAN POTASSIUM; OLMESARTAN; PLACEBO; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HUMAN; HYPERTENSION; HYPERTENSION STAGE 1; HYPERTENSION STAGE 2; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LEAST-SQUARES ANALYSIS; LOSARTAN; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84867886614     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2549     Document Type: Article

References (24)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20): 2043-2050.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
3. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45(5):907-913.
4. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153(5):598-615.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
6. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
7. Mustone Alexander L. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs. 2006;66(9):1239-1252.
8. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens. 2010;12(11):869-878.
9. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. 2005;18(2 pt 1):287-294.
10. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41-50.
11. Neutel JM, Smith DH, Silfani TN, Lee Y, Weber MA. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens. 2006;20(4):255-262.
12. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(suppl 1):S73-S86.
13. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 2003;17(6):425-432.
14. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Managed Care Pharm. 2003;9(5):424-429.
15. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18(6):649-656.
16. Gregoire J, Moisan J, Guibert R, Ciampi A, Milot A. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can J Cardiol. 2006;22(4):323-329.
17. Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update. Publication no. 11-EHC063-EF June 2011. Rockville, MD. Agency for Healthcare and Research Quality; 2011.
18. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283-291, 318.
19. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187-195.
20. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207-1225.
21. Liau CS, Lee CM, Sheu SH, et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients. Clin Drug Investig. 2005;25(7):473-479.
22. Weir MR, Punzi HA, Flack JM, et al. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgrad Med. 2011;123(1):80-87.
23. Flack JM, Sica DA, Bakris G, et al; International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56(5):780-800.
24. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716.